NHC Stock Analysis: National HealthCare | AMEX
Medical Care Facilities | AMEX, USA | Market Cap: 3.471m USD | 12M Return: 89.1% | US6359061008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.8M
EPS Trend: 80.5%
Rev. Trend: 98.2%
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
National HealthCare Corporation (NHC) operates an integrated continuum of senior care and health services across two reportable segments: Inpatient (skilled nursing, assisted and independent living, behavioral health, and hospital operations) and Homecare and Hospice Services. The companys skilled nursing facilities provide physician-directed medical care, licensed therapy (physical, speech, respiratory, occupational), nutrition, and social services, with specialty units dedicated to memory care and sub-acute nursing. NHC also operates assisted and independent living residences, homecare and hospice agencies, pharmacies, and managed care insurance solutions, while leasing certain properties to third-party operators and providing management and financial services to affiliated entities.
The company was founded in 1971 and is headquartered in Murfreesboro, Tennessee, and has traded on the AMEX under the ticker NHC since its 1987 IPO. As a mid-cap stock in the Health Care Facilities sub-industry, NHCs business model spans the post-acute and senior housing value chain, addressing the demographic-driven demand for long-term care, rehabilitation, and behavioral health services in the United States.
- Medicare and Medicaid reimbursement changes drive inpatient segment revenue
- Aging population tailwind expands homecare and hospice services
- Nursing wage inflation pressures operating margins across facilities
| Net Income: 140.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.11 > 1.0 |
| NWC/Revenue: 24.71% < 20% (prev 13.34%; Δ 11.38% < -1%) |
| CFO/TA 0.12 > 3% & CFO 188.8m > Net Income 140.3m |
| Net Debt (-183.7m) to EBITDA (233.6m): -0.79 < 3 |
| Current Ratio: 22.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.9m) vs 12m ago 1.70% < -2% |
| Gross Margin: 39.49% > 18% (prev 38.11%; Δ 1.37% > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 93.34%; Δ 7.27% > 0%) |
| Interest Coverage Ratio: 73.58 > 6 (EBIT TTM 187.9m / Interest Expense TTM 2.55m) |
| A: 0.25 (Total Current Assets 403.6m - Total Current Liabilities 18.3m) / Total Assets 1.54b |
| B: 0.58 (Retained Earnings 888.7m / Total Assets 1.54b) |
| C: 0.12 (EBIT TTM 187.9m / Avg Total Assets 1.55b) |
| D: 2.74 (Book Value of Equity 1.12b / Total Liabilities 408.9m) |
| Altman-Z'' = 7.23 = AAA |
| DSRI: 0.91 (Receivables 137.7m/142.1m, Revenue 1.56b/1.46b) |
| GMI: 0.97 (GM 38.11% / 39.49%) |
| AQI: 1.06 (AQ_t 0.24 / AQ_t-1 0.23) |
| SGI: 1.07 (Revenue 1.56b / 1.46b) |
| TATA: -0.03 (NI 140.3m - CFO 188.8m) / TA 1.54b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at USD 227.36 with a total of 152,676 shares traded. Over the past week, the price has changed by +2.36%, over one month by +1.17%, over three months by +13.18% and over the past year by +89.14%.
Current recommended Stop Loss: 219.00 (which is 3.7% or 1.3 ATR below the current price).
National HealthCare has no consensus analysts rating.
| Analysts Target Price | 6.2 | -97.3% |
P/E Trailing = 25.2392
P/E Forward = 9.8912
P/S = 2.2261
P/B = 3.138
P/EG = 0.8241
Revenue TTM = 1.56b USD
EBIT TTM = 187.9m USD
EBITDA TTM = 233.6m USD
Long Term Debt = 32.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 82.2m USD (corrected: LT Debt 32.5m + ST Debt 18.3m) + Leases 31.4m
Net Debt = -183.7m USD (calculated: Debt 82.2m - CCE 265.9m)
Enterprise Value = 3.29b USD (3.47b + Debt 82.2m - CCE 265.9m)
Interest Coverage Ratio = 73.58 (Ebit TTM 187.9m / Interest Expense TTM 2.55m)
EV/FCF = 22.43x (Enterprise Value 3.29b / FCF TTM 146.5m)
FCF Yield = 4.46% (FCF TTM 146.5m / Enterprise Value 3.29b)
FCF Margin = 9.40% (FCF TTM 146.5m / Revenue TTM 1.56b)
Net Margin = 9.00% (Net Income TTM 140.3m / Revenue TTM 1.56b)
Gross Margin = 39.49% ((Revenue TTM 1.56b - Cost of Revenue TTM 943.4m) / Revenue TTM)
Gross Margin QoQ = 40.71% (prev 38.43%)
Tobins Q-Ratio = 2.14 (Enterprise Value 3.29b / Total Assets 1.54b)
Interest Expense / Debt = 3.11% (Interest Expense 2.55m / Debt 82.2m)
Taxrate = 22.94% (42.5m / 185.4m)
NOPAT = 144.8m (EBIT 187.9m * (1 - 22.94%))
Current Ratio = 22.06 (Total Current Assets 403.6m / Total Current Liabilities 18.3m)
Debt / Equity = 0.07 (Debt 82.2m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = -0.79 (Net Debt -183.7m / EBITDA 233.6m)
Debt / FCF = -1.25 (Net Debt -183.7m / FCF TTM 146.5m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 140.3m / Total Assets 1.54b)
RoE = 12.94% (Net Income TTM 140.3m / Total Stockholder Equity 1.08b)
RoCE = 16.83% (EBIT 187.9m / Capital Employed (Equity 1.08b + L.T.Debt 32.5m))
RoIC = 9.93% (NOPAT 144.8m / Invested Capital 1.46b)
WACC = 7.25% (E(3.47b)/V(3.55b) * Re(7.36%) + D(82.2m)/V(3.55b) * Rd(3.11%) * (1-Tc(0.23)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.38 | Cagr: 1.02%
[DCF] Terminal Value 77.97% ; FCFF base≈128.1m ; Y1≈146.8m ; Y5≈216.1m
[DCF] Fair Price = 219.4 (EV 3.25b - Net Debt -183.7m = Equity 3.44b / Shares 15.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 30.16% | SUE: N/A | # QB: 0
Revenue Correlation: 98.20 | Revenue CAGR: 15.02% | SUE: N/A | # QB: 0